The Great Cell and Gene Therapy Reckoning: From Revolutionary Promise to Industry Crossroads

Just days ago, on October 21, Belgian biotech Galapagos became the latest major casualty in what can only be described as a crisis of confidence sweeping through the cell and gene therapy CCGTF sector. The company announcedHiI it would shutter its entire cell therapy division: cutting 365 jobs and closing facilities across the Netherlands, Switzerland, the United States, and China. This after failing to find a single viable buyer for assets it had desperately tried to offload.